Other News To Note
Cell Therapeutics Inc. (CTI), of Seattle, said the FDA granted orphan drug designation to Opaxio (paclitaxel poliglumex), formerly known as Xyotax, in glioblastoma multiforme (GBM) based on preliminary activity seen in Phase II results of Opaxio when added to standard therapy (temozolamide, or TMZ, plus radiation). The study showed encouraging progression-free and overall survival among patients with GBM, including those whose tumors expressed unmethylated MGMT.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST